Vaccines are changing the course of the COVID-19 pandemic, but in grossly uneven ways. Low- and middle-income countries (LMICs) face considerable obstacles in both receiving and distributing doses. To limit virus transmission, its devastating impacts, and opportunities for further mutations, this must change. Until it does, nonpharmaceutical interventions such as masking must remain a priority. Science invited global experts to highlight research and innovations aimed at quickening the end of COVID-19 in LMICs.
No takes yet. Share an insight, caveat, or question.
Mobarak et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: